Biblio
The Rational Development of CD133-Targeting Immunotherapies for Glioblastoma. Cell Stem Cell. 2020.
Characterization of the minimal residual disease state reveals distinct evolutionary trajectories of human glioblastoma. Cell Rep. 2022;40(13):111420.